In Vivo mRNA-Engineered CAR-Macrophage Therapy for Hepatocellular Carcinoma Enters Clinical Translation
Carisma Therapeutics
Developer of Cell Immunotherapy
In2024Year9Month6Held in Beijing, the 8th Conference on Immunogenetics and Cell Therapy2024Year7International Society for Stem Cell Research held in Hamburg, Germany in June（ISSCR） At the annual meeting,Researchers from the founding team of Carisma Therapeutics have donemRNAMediated In Vivo EditingCAR-Macrophages forReport on Immunotherapy for Liver Cancer.
The researchers adoptedLNP-mRNAThe system has designed a product that includes4A product that uses components to enhance the anti-tumor effects of immune cells, respectively targeting liver cancer antigens.GPC3TheCARUsed to increaseCAR-Tumor-specific targeting of macrophages;Targeting the Physical Barriers of Tumors to Enhance Immune Cell Infiltration; Components3And Components4The purpose is to improve the tumor microenvironment and provide specific stimulation.CD8CytotoxicityTCell activity. In preclinical models of primary liver cancer, this product demonstrated excellent anti-tumor effects,80%Individuals in the treated group achieved complete remission and demonstrated strong anti-relapse characteristics through epitope spreading after remission. No toxicity was observed in organs such as the heart, lungs, and kidneys.
Right at2024Year6Month27Day,United StatesmRNAPharmaceutical R&D GiantModernaAndR&DCARBiotech Company for Macrophage ProductsCarisma TherapeuticsAnnouncementIts cooperationThe First In Vivo Editing for Liver CancerGPC3-CAR-MacrophageCandidate drug,Carisma TherapeuticsBy this means, it is completed.SuccessMillions of dollarsTheR&DMilestone. This cooperation progress embodiesMNCIn vivo editingCAR-Confidence in the new track of macrophage drugs.
Recommended reading article link:The vitreous retina team of the ophthalmology department at the Second Affiliated Hospital of Zhejiang University completed the first gene therapy treatment for wet age-related macular degeneration (nAMD) in Zhejiang Province.
E.N.D
Article Recommendation(Click the article title below to open the original text)：
U.S. Biosecurity Act Passes with 306:81 Vote
AAV Gene Therapy Improves Patients' Vision Over a Hundredfold
Ruishun Biologics' World's First Non-Gene-Edited Universal CAR-DNT Cell Therapy Approved for IND
MediCI R&D Center Officially Begins Operations
Former President of Innovent Biologics, Liu Yongjun, Takes New Role at CSPC Pharmaceutical Group
A CRO Company in China Listed on the STAR Market
Anling Biotech Launches Two Exosome Therapy Clinical Trials Simultaneously
This company obtains the first Stem Cell Drug Manufacturing License in China
Effective September 1! Shanghai Releases CAR-T Cell Therapy Drug Supervision Regulations
Cell Therapy Company Xueji Bio Completes New Round of Financing
Another Cell and Gene Therapy Product Approved for Marketing in China
World's First mRNA Lung Cancer Vaccine Clinical Trial Launched
γ-δ T Cell Therapy: 100% of Patients Achieved Complete Tumor Disappearance and Maintained for 1 Year
CD19/CD20 Dual-Target CAR-T Approved for Clinical Use in Treating Autoimmune Diseases